Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese SubjectsAn Open-Label, Single-Center, First-in-Human Study

被引：15

作者：

Luning Sun

Li Ding

Yongqing Wang

Wenjia Zhou

Zhengyu Yan

Weilin Sun

Hongwen Zhang

Ning Ou

Xiaoping Chen

机构：

[1] China Pharmaceutical University,

[2] First Affiliated Hospital of Nanjing Medical University,undefined

[3] Beijing Shiqiao Biological and Pharmaceutical Co. Ltd,undefined

来源：

Drugs in R&D | 2012年 / 12卷 / 1期

关键词：

Rhinitis; Intranasal Administration; Ipratropium Bromide; Lateral Nasal Wall; Aclidinium;

D O I：

10.2165/11599330-000000000-00000

中图分类号：

学科分类号：

摘要：

Background: Bencycloquidium bromide (BCQB) is a novel, potent and selective muscarinic M1/M3 receptor antagonist under development for the treatment of rhinorrhea in rhinitis. The pharmacokinetics and safety of BCQB in animals have been established in preclinical studies. However, no clinical pharmacokinetic data are available for BCQB in humans.

引用

页码：17 / 28

页数：11